Semaglutide and tirzepatide are the two biggest names in the weight-loss peptide world, and for years comparing them meant matching one trial against another rather than testing them directly. That changed in 2025, when the first head-to-head study finally put them in the same trial. The short version: tirzepatide came out ahead on weight loss. The more useful version is about why, and about the factors that live beyond the scale.
How They Work: One Pathway vs. Two
Both are once-weekly injectable peptides that reduce appetite, but they engage different receptors, and that difference drives everything else. Semaglutide is a GLP-1 receptor agonist: it activates a single incretin pathway that suppresses appetite and slows gastric emptying. Tirzepatide is a dual agonist, activating both the GLP-1 receptor and the GIP receptor. That second pathway is the difference-maker and the leading explanation for tirzepatide’s stronger results, because combining two complementary appetite-regulating mechanisms tends to overcome the plateau that a single mechanism runs into.
| Factor | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist (single) | GIP + GLP-1 dual agonist |
| Weight loss (head-to-head) | ~13.7% at 72 weeks | ~20.2% at 72 weeks |
| Waist reduction | ~13.0 cm | ~18.4 cm |
| Dosing | Once-weekly injection | Once-weekly injection |
| GI discontinuation | Slightly higher | Slightly lower |
| Brand names | Ozempic / Wegovy | Mounjaro / Zepbound |
The Head-to-Head Result
For years the comparison relied on cross-trial math: semaglutide produced about 15% weight loss in its STEP-1 trial, and tirzepatide roughly 21% in SURMOUNT-1. But those were different trials with different participants, so the comparison was suggestive rather than definitive. The first direct head-to-head trial, SURMOUNT-5, settled it far more cleanly. Over 72 weeks in 751 adults with obesity, tirzepatide produced a mean weight reduction of about 20.2% versus 13.7% for semaglutide, along with greater waist-circumference reduction. Nearly one in five tirzepatide users lost at least 30% of their body weight, compared with about one in fourteen on semaglutide. On average, tirzepatide users lost close to 50% more weight.
Side Effects and Tolerability
On safety, the two were more alike than different. Both cause mainly gastrointestinal side effects, nausea and digestive upset, concentrated during the dose-escalation period. Notably, in the head-to-head trial, gastrointestinal side effects leading to discontinuation were slightly more common with semaglutide than with tirzepatide, and serious adverse events were similar between the groups. Neither drug showed a safety signal that clearly sets it apart from the other, so tolerability is roughly a wash, with a slight edge to tirzepatide on discontinuations.
Beyond the Scale
Weight loss is not the only axis worth weighing. Semaglutide has the longer track record and dedicated cardiovascular-outcomes evidence behind it, which matters a great deal to many users and prescribers. Cost, insurance coverage, and supply differ by market and change frequently. And individual response genuinely varies: some people tolerate or respond to one better than the other, a pattern also visible in real-world comparisons outside the controlled-trial setting. On average it is not the same as for everyone.
The Verdict
On the single question of weight loss, tirzepatide comes out ahead, and now has direct head-to-head evidence to prove it rather than just favorable cross-trial comparisons. Its dual GIP and GLP-1 mechanism appears to be the reason. But weight loss is not the same as better for everyone. Semaglutide’s longer record, its cardiovascular data, and differences in cost and access keep it firmly relevant. The honest bottom line: tirzepatide is the more powerful weight-loss agent, while the right choice still depends on the whole picture, not just the percentage on the scale.
Both of these are prescription medications rather than research chemicals, and this comparison is informational, not a sourcing guide. For researchers working with metabolic peptides in a laboratory setting, sourcing quality is its own variable, since an impure or mislabeled sample undermines any result. Suppliers such as Omni Peptides provide batch-specific Certificates of Analysis and independent third-party testing, the baseline any serious researcher should expect.
Frequently Asked Questions
Which is better for weight loss, semaglutide or tirzepatide?
In the head-to-head SURMOUNT-5 trial, tirzepatide produced significantly more weight loss than semaglutide (about 20.2% versus 13.7% over 72 weeks).
Why does tirzepatide cause more weight loss?
Tirzepatide activates two receptors (GIP and GLP-1) rather than semaglutide’s one (GLP-1). The added GIP pathway is credited with the greater effect.
Are the side effects different?
Both cause mainly gastrointestinal effects and are broadly comparable, though in the head-to-head trial, discontinuations from GI side effects were slightly more common with semaglutide.
Is semaglutide still worth considering?
Yes. It has a longer track record, dedicated cardiovascular-outcomes data, and different cost and access, all of which can make it the better fit for a given person.
This article is for informational purposes and summarizes published research. Semaglutide and tirzepatide are prescription medications; nothing here is medical advice or a recommendation to use, obtain, or source either compound. Consult a licensed clinician for medical decisions.
